Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb succession

Executive Summary

Confirmation of Wayne Davidson as the top pharmaceutical officer in the combined businesses has rekindled interest in the post-Gelb management. Chairman Richard Gelb has set June 1993 as the target for his retirement. At that date, current Vice Chairman William Miller will be 64. Likely replacement will come from current triumverate of exec VPs: Davidson, Charles Heimbold and Michael Autera. Heimbold, 56, has responsibility for consumer products, the health care group (medical devices) and planning and development. Autera is chief financial officer and head of administration, a key post in a major merger period.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel